Table 4.
Summary of TSS in CTCL biopsies taken from patients treated with PXD101, depsipeptide, or LBH589
TSS | PR/SD | PD | Total |
≥6 | 9 | 4 | 13 |
<6 | 4 | 4 | 8 |
Total | 13 | 8 | 21 |
Distribution of patients categorized as having high (≥6) or low (<6) TSS for HR23B according to response to treatment (PR/SD) or no response (PD) in patients treated with PXD101, depsipeptide, or LBH589. Positive predictive value: 64.7%.